Watchful waiting versus prostatectomy for prostate cancer

Cochrane Database of Systematic Reviews

Volumn , Issue 3, 2007, Pages

  Hegarty, J ^b   Beirne, P ^b   Comber, H ^b   Wallace, Meredith ^a  

^a FAIRFIELD UNIVERSITY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CANCER SURVIVAL; CLINICAL PROTOCOL; CLINICAL TRIAL; COMPARATIVE STUDY; HUMAN; PROSTATE CANCER; PROSTATECTOMY; QUALITY OF LIFE; RANDOMIZATION; REVIEW; RISK BENEFIT ANALYSIS; SYSTEMATIC REVIEW; TREATMENT OUTCOME; WATCHFUL WAITING;

EID: 44949121695     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD006590     Document Type: Review

References (33)

1. Albertsen 2005 Albertsen PC, Hanley JA, Fine J. 20-Year Outcomes Following Conservative Management of Clinically Localized Prostate Cancer. JAMA 2005;293(17):2095-2101.
2. Alivizatos 2005 Alivizatos G, Skolarikos A. Incontinence and erectile dysfunction following radical prostatectomy: a review. The Scientific World Journal 2005;5:747-758.
3. Aus 2005 Aus G, Abbou CC, Bolla M, Heidenreich A, van Poppel H, Schmid H-P, Wolff JM, Zattoni F. Guidelines on prostate cancer. European Association of Urology 2005; Vol. March:1-106, http://www.uroweb.nl/files/ uploaded_files/2005Prostate%20Cancer.pdf.
4. Auvinen 2004 Auvinen A, Hakama M, Ala-Opas M, Vornanen T, Leppilahti M, Salminen P, Tammela TLJ. A randomized trial of choice of treatment in prostate cancer: the effect of intervention on treatment chosen. BJU International 2004;93:52-56..
5. Bill-Axelson 2005 Bill-Axelson, A, Holmberg L, Ruutu M, Haggman M, Andersson SO, Bratell S, Spangberg A, Busch C, Nordling S, Garmo H, Palmgren J, Adami HO, Norlen BJ, Johansson, JE. Radical prostatectomy versus watchful waiting in early prostate cancer. The New England Journal of Medicine 2005;352(19):1977-1984.
6. Bott 2003 Bott SRJ, Birtle AJ, Taylor CJ, Kirby RS. Prostate cancer management: (1) an update on localised disease. Postgrad Med J 2003;79:575-580.
7. Bunting 2002 Bunting PS. Screening for prostate cancer with prostate-specific antigen: beware the biases. Clinica Chimica Acta 2002;315:71-97.
8. Carter 2003 Carter CA, Donahue T, Sun L, Wu H, McLeod DG, Ampling C, Lance R, Foley J, Sexton W, Kusuda L, Chung A, Soderdahl D, Jackman S, Moul JW. Temporarily deferred therapy (watchful waiting) for men younger than 70 years and with low-risk localized prostate cancer in the Prostate-Specific Antigen Era. Journal of Clinical Oncology 2003;21(21):4001-4008.
9. Choo 2004 Choo R, Klotz L, Deboer G, Danjoux C, Morton GC. Wide variation of prostate-specific antigen doubling time of untreated, clinically localized, low to intermediate grade, prostate cancer. BJU International 2004;94:295-298.
10. El-Geneidy 2004 El-Geneidy M, Garzotto M, Panagiotou I, Hsieh Y-C, Mori M, Peters L, Klein T, Beer TM. Delayed therapy with curative intent in a contemporary prostate cancer watchful-waiting cohort. BJU International 2004;93:510-515.
11. Frankel 2003 Frankel S, Davey Smith G, Donovan J, Neal D. Screening for prostate cancer. Lancet 2003;361:1122-1128.
12. Hardie 2005 Hardie C, Parker C, Norman A, Eeles R, Horwich A, Huddart R, Dearnaley D. Early outcomes of active surveillance for localised prostate cancer. BJU International 2005;95:956-960.
13. Hu 2004 Hu JC, Elkin EP, Pasta DJ, Lubeck DP, Kattan MW, Carroll PR, Litwin MS. Predicting quality of life after radical prostatectomy results from CaPSURE. The Journal of Urology 2004;171:703-708.
14. Ilic 2006 Ilic D, O'Connor D, Green S, Wilt T. Screening for prostate cancer. Cochrane Database of Systematic Reviews 2006, Art.No.: CD004720.DOI:10.1002/14651858.CD004720.pub2., Issue 3.
15. Jani 2003 Jani AB, Hellman S. Early prostate cancer: clinical decision making. The Lancet 2003;361:1045-1053.
16. Johansson 2004 Johansson JE, Andrén O, Andersson S-O, Dickman PW, Holmberg L, Magnuson A, Adami H-O. Natural History of ealy, localized prostate cancer. JAMA 2004;291(22):2713-2719.
17. Klotz 2005 Klotz LH. Active surveillance for good risk prostate cancer: rationale, method and results. The Canadian Journal of Urology 2005;12(2):21-4.
18. Klotz 2006 Klotz L, Nam R. Active surveilance with selective delayed intervention for favourable risk prostate cancer: clinical experience and a "number needed to treat" analysis. European Urology Supplements 2006;5:479-486.
19. Kumar 2006 Kumar S, Shelley M, Harrison C, Coles B, Wilt TJ, Mason MD. Neoadjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer. Cochrane Database of Systematic Reviews 2006, Issue 4.Art. No.: CD006019. DOI:10.1002/14651858.CD006019.pub2.
20. Meyer 2003 Meyer JP, Gillatt DA, Lockyer R, MacDonagh R. The effect of erectile dysfunction on the quality of life of men after radical prostaectomy. BJU International 2003;92:929-931.
21. Myers 2001 Myers RP. Radical prostatectomy: making it a better operation in the new millennium. International Journal of Urology 2001;8:S9-S14.
22. Namiki 2004 Namiki S, Tochigi T, Kuwahara M, Ioritani N, Terai A, Numata I, Satoh M, Saito S, Koinuma N, Arai Y. Health related quality of life in Japanese men after radical prostatectomy or radiation therapy for localized prostate cancer. International Journal of Urology 2004;11:619-627.
23. Neulander 2000 Neulander EZ, Duncan RC, Tiguert R, Posey JT, Soloway MS. Deferred treatment of localized prostate cancer in the elderly: the impact of the age and stage at the time of diagnosis on the treament decision. BJU International 2000;85:699-704.
24. Parker 2003 Parker C. Active surveillance: an individualized approach to early prostate cancer. BJU International 2003;92(1):2- 3.
25. Parker 2006 Parker C, Muston D, Melia J, Moss S, Dearnaley D. A model of the natural history of screen-detected prostate cancer, and the effect of radical treatment on overall survival. British Journal of Cancer 2006;94:1361-1368.
26. Parkin 2005 Parkin MD, Bray F, Ferlay J, Pisani P. Global Cancer Statistics, 2002. Cancer Journal for Clinicians, American Cancer Society 2005;55:74-108.
27. Parmer 1998 Parmer MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of published literature for survival endpoints. Statistics in Medicine 1998;17:2815-34.
28. Schmid 2001 Schmid HP, Adolfsson J, Aus G. Active Monitoring (Deferred Treatment or Watchful waiting) in the treatment of Prostate Cancer. A Review. European Urology 2001;40:488-494.
29. Schroder 2003 Schroder FH, de Vries SH, Bangma CH. Watchful waiting in prostate cancer: review and policy proposals. BJU International 2003;92:851-859.
30. Wei 2002 Wei JT, Dunn RL, Sandler HM, McLoughlin W, Montie JE, Liwin MS, Nyquist L, Sanda MG. Comprehensive comparison of health-related quality of life after contemporary therapies for localized prostate cancer. Journal of Clinocal Oncology 2002;20(2):557-566.
31. Wilt 1994 Wilt TJ, Brawer MK. The prostate cancer intervention versus observation trial: a randomised trial comparing radical prostatectomy versus expectant management for the treatment of clinically localized prostate cancer. The Journal of Urology 1994;152:1910-1914.
32. Wong 2006 Wong YN, Mitra N, Hudes G, Localio R, Schwartz JS, Wan F, Montagnet C, Armstrong K. Survival associated with treatment vs observation of localized prostate cancer in elderly men. JAMA 2006;296(22): 2683-2693.
33. Zeliadt 2006 Zeliadt SB, Ramsey SD, Penson DF, Hall IJ, Ekwueme DU, Stroud L, Lee JW. Why domen choose one treatment over another? A review of patient decision making for localized prostate cancer. Cancer 2006;106:1865-1874.